Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Imaging

Esmo 6 Imaging

In this session, the speakers discuss the uses and clinical trials of Radium 223 therapy . They discuss the key issues in imaging in advanced prostate cancer. They also discuss  patient selection (low- versus. high-volume disease, oligo- vs. polymetastatic disease, aggressive disease detection), treatment benefit (radiographic progression-free survival, lack of bone metastases response on imaging criteria, emerging prostate-specific membrane antigen [PSMA]-targeting molecules as treatment under development). They mention that whole-body magnetic resonance imaging (MRI) - diffusion-weighted imaging (DWI) has potential as ‘one-stop shop’ instead of MRI prostate + CT + bone scan. On comparison of PSMA with whole body markers, Dr. Tunariu mentions that PSMA gives detection while whole body markers give information about response to therapy. They discuss that bone scan has  limitations such as being more sensitive to progression than response, assessment of hydroxyapatite deposition but not to cancer, qualitative rather than quantitative, subject to flare-ups. The Prostate Cancer Working Group (PCWG) criteria focus not on imaging but on biomarker development and presence of absence of two new lesions. 

Next video

  • Additional materials on imaging in advanced prostate cancer:

    Abstract 750P: Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)

    Saad et al.

    Annals of Oncology 27 (Supplement 6): vi243-vi265, 2016

    Link to full-article: http://annonc.oxfordjournals.org/content/27/suppl_6/750P.full.pdf


    Abstract 751P: Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early ` access program (EAP)

    Heinrich et al.

    Annals of Oncology 27 (Supplement 6): vi243-vi265, 2016

    Link to full-article: http://annonc.oxfordjournals.org/content/27/suppl_6/751P.full.pdf


    Abstract 752P: Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases

    Sartor et al.

    Annals of Oncology 27 (Supplement 6): vi243-vi265, 2016

    Link to full-article: http://annonc.oxfordjournals.org/content/27/suppl_6/752P.full.pdf

  • Radium-223 (Ra-223) re-treatment (Re-tx): First experience from international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC).

    Sartor et al.

    J Clin Oncol 34, 2016 (suppl 2S; abstr 197) ASCO 2016 Genitourinary Cancers Symposium.

    Link to full-article: http://meetinglibrary.asco.org/content/157685-172


    Rationale for Modernising Imaging in Advanced Prostate Cancer

    Padhani AR, Lecouvet FE, Tunariu N, Koh D-M, De Keyzer F, Collins DJ et al.

    Eur Urol Focus, 2016 [Epub ahead of print]

    Link to full-article: http://advancedprostatecancer.elsevierresource.com/articles/rationale-modernising-imaging-advanced-prostate-cancer


    Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging

    Barentsz JO, Mulders P, Gerritsen W, Fütterer JJ

    Eur Urol 2017;71:93-95.

    Link to full-article: http://advancedprostatecancer.elsevierresource.com/articles/assessing-metastatic-disease-advanced-prostate-cancer-its-time-change-imaging


    METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer

    Padhani AR, Lecouvet FE, Tunariu N, Koh D-M, De Keyzer F, Collins DJ et al.

    Eur Urol 2017;71:81-92.

    Link to full-article: http://advancedprostatecancer.elsevierresource.com/metastasis-reporting-and-data-system-prostate-cancer-practical-guidelines-acquisition-interpretation


    Prostate cancer: Birth of a standard: MET-RADS-P for metastatic prostate cancer

    Turkbey B, Choyke PL

    Nat Rev Urol. 2016;13:568-70.

    Link to full-article: https://www.ncbi.nlm.nih.gov/pubmed/27578044


    Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results

    Morris MJ, Molina A Small EJ, de Bono JS, Logothetis CJ, Fizazi K, et al.

    J Clin Oncol 2015;33:1356-63.

    link to full-article: https://www.ncbi.nlm.nih.gov/pubmed/?term=25624432


    Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al.

    J Clin Oncol 2016;34:1402-18.

    Link to full-article: https://www.ncbi.nlm.nih.gov/pubmed/?term=26903579

  • ESMO 2016 presented posters will be included here

    750P: Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)


    751P: Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)


    752P: Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases